6-Chloroimidazo[1,2-b]pyridazine for Kinase Inhibitor Cross-Coupling
Steric and Electronic Modulation of the C6-Chloro Position in 6-Chloroimidazo[1,2-b]pyridazine for Palladium-Catalyzed Cross-Coupling
The imidazo[1,2-b]pyridazine scaffold is a privileged heterocyclic core in kinase inhibitor design, and the C6-chloro substituent in 6-Chloroimidazo[1,2-b]pyridazine (CAS 6775-78-6) serves as a versatile handle for late-stage functionalization. In our hands, the chlorine atom at the 6-position exhibits a unique balance of steric accessibility and electronic activation, enabling efficient oxidative addition with Pd(0) catalysts. However, we have observed that the electron-withdrawing nature of the adjacent pyridazine nitrogen can retard the transmetallation step in Suzuki-Miyaura couplings when using electron-deficient boronic acids. To compensate, we recommend a slight excess (1.2–1.5 equiv) of the boronate partner and the use of SPhos or XPhos ligands, which enhance the nucleophilicity of the palladium center. For Buchwald-Hartwig aminations, the C6-chloro position reacts smoothly with primary and secondary amines under standard conditions (Pd2(dba)3, BrettPhos, NaOtBu, dioxane, 100°C), but we have encountered sluggish reactions with sterically hindered anilines. In such cases, switching to the more reactive 6-bromo analog or employing a two-step sequence via the 6-iodo derivative (prepared in situ via Finkelstein reaction) can improve conversion. As a drop-in replacement for Sigma-Aldrich CPR CDS005940, our 6-Chloroimidazo[1,2-b]pyridazine delivers identical reactivity profiles, as detailed in our comparative study on substituindo Sigma-Aldrich CPR CDS005940. For researchers scaling up, we also provide insights on bulk handling in our article on reemplazo de Sigma-Aldrich CPR CDS005940.
Impact of Trace Transition Metal Residues on Suzuki-Miyaura Coupling Efficiency and Mitigation via Chelating Wash Protocols
One often-overlooked factor in cross-coupling optimization is the presence of trace transition metal impurities in the starting 6-Chloroimidazo[1,2-b]pyridazine. Residual iron, copper, or nickel from the manufacturing process can poison palladium catalysts or promote unwanted homocoupling of the boronic acid. In our production, we have identified that iron residues as low as 50 ppm can reduce the turnover number by up to 30% in a model Suzuki reaction with phenylboronic acid. To address this, we have implemented a proprietary chelating wash protocol using aqueous EDTA or NTA solutions during the final purification, which consistently reduces total transition metal content to below 10 ppm. For end-users, we recommend a simple pre-treatment: dissolve the 6-Chloroimidazo[1,2-b]pyridazine in dichloromethane, wash with 5% aqueous EDTA, dry over MgSO4, and filter through a plug of activated charcoal. This step is particularly critical when using low catalyst loadings (0.1–0.5 mol% Pd). Additionally, we have observed that the imidazo[1,2-b]pyridazine 6-chloro can form stable complexes with copper, leading to a greenish discoloration in aged samples. This does not affect reactivity but can be removed by the same EDTA wash. For sensitive kinase inhibitor projects, we supply a high purity reagent grade with guaranteed metal specifications, as detailed in the batch-specific COA.
Preventing Polymorphic Shifts: Purification Strategies to Maintain Bioassay Solubility in Kinase Inhibitor Synthesis
6-Chloroimidazo[1,2-b]pyridazine is known to exist in at least two polymorphic forms, which can impact solubility and, consequently, the performance in biological assays. The thermodynamically stable Form I (obtained by slow cooling from ethanol) exhibits poor aqueous solubility (<0.1 mg/mL), while the metastable Form II (obtained by rapid precipitation from dichloromethane/hexane) shows a 5-fold higher solubility. In our experience, the polymorphic outcome is highly dependent on the final recrystallization solvent and cooling rate. For medicinal chemists, we recommend using the material as received without further recrystallization, as our standard manufacturing process consistently delivers Form II. However, if recrystallization is necessary, we advise using a solvent system that includes a hydrogen bond acceptor (e.g., ethyl acetate or acetone) to stabilize the metastable form. We have also observed that the presence of trace water can induce a polymorphic shift during storage; therefore, we package our 6-Chloroimidazo[1,2-b]pyridazine under argon in sealed, moisture-resistant containers. For long-term storage, we recommend keeping the material at -20°C. As a pharmaceutical intermediate, this compound is a key building block in the synthesis of Cefozopran and other β-lactam antibiotics, and its consistent physical form is crucial for reproducible process chemistry.
Batch-Specific COA Parameters and Bulk Packaging Specifications for 6-Chloroimidazo[1,2-b]pyridazine (CAS 6775-78-6)
At NINGBO INNO PHARMCHEM, we provide a comprehensive Certificate of Analysis (COA) with every batch of 6-Chloroimidazo[1,2-b]pyridazine. The following table summarizes the typical specifications for our standard and high-purity grades. Please refer to the batch-specific COA for exact values.
| Parameter | Standard Grade | High Purity Grade |
|---|---|---|
| Assay (HPLC) | ≥98.0% | ≥99.5% |
| Appearance | Off-white to pale yellow powder | White crystalline powder |
| Water Content (KF) | ≤0.5% | ≤0.1% |
| Total Heavy Metals (as Pb) | ≤20 ppm | ≤10 ppm |
| Residual Solvents | Meets USP <467> | Meets USP <467> with lower limits |
| Polymorphic Form | Form II (metastable) | Form II (metastable) |
For bulk supply, we offer standard packaging in 25 kg fiber drums with double PE liners, as well as 210L steel drums for larger quantities. IBC totes are available upon request for ton-scale orders. All packaging is performed under inert atmosphere to ensure long-term stability. Our manufacturing process is optimized for cost-efficiency without compromising quality, making us a reliable global manufacturer for this heterocyclic building block. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.
Frequently Asked Questions
What catalyst loading adjustments are recommended when using 6-Chloroimidazo[1,2-b]pyridazine in Suzuki couplings with electron-deficient boronic acids?
For electron-deficient boronic acids, we typically increase the Pd catalyst loading to 2–5 mol% and use SPhos or XPhos as the ligand. The addition of 1–2 equivalents of water can also accelerate the transmetallation step. Pre-activation of the boronic acid as the corresponding trifluoroborate salt is an alternative strategy.
How does solvent polarity affect the coupling yield of 6-Chloroimidazo[1,2-b]pyridazine in Buchwald-Hartwig aminations?
We have found that a mixture of dioxane and toluene (1:1) often provides optimal yields for aminations with primary amines. For secondary amines, pure dioxane is preferred. Highly polar solvents like DMF or DMSO can lead to increased dehalogenation side products.
What analytical methods can detect trace metal carryover in 6-Chloroimidazo[1,2-b]pyridazine without relying on standard purity metrics?
Inductively coupled plasma mass spectrometry (ICP-MS) is the most sensitive method for quantifying trace metals. For routine monitoring, we use a colorimetric test with dithizone, which can detect heavy metals at ppm levels. Additionally, a simple flame test on the residue after ignition can indicate the presence of sodium or potassium salts.
Can 6-Chloroimidazo[1,2-b]pyridazine be used directly in Sonogashira couplings, or is a halogen exchange necessary?
The C6-chloro position is sufficiently reactive for Sonogashira couplings with terminal alkynes using Pd(PPh3)2Cl2/CuI as the catalyst system. However, for sluggish substrates, we recommend in situ conversion to the 6-iodo derivative using NaI and a catalytic amount of CuI in dioxane at reflux.
What is the recommended storage condition to prevent degradation of 6-Chloroimidazo[1,2-b]pyridazine?
Store in a tightly sealed container under inert gas (argon or nitrogen) at -20°C. Protect from light and moisture. Under these conditions, the material is stable for at least 24 months.
Sourcing and Technical Support
NINGBO INNO PHARMCHEM is committed to providing high-quality 6-Chloroimidazo[1,2-b]pyridazine as a reliable drop-in replacement for your kinase inhibitor and pharmaceutical intermediate needs. Our product, with CAS 6775-78-6, is manufactured under strict quality control to ensure batch-to-batch consistency. We understand the criticality of this heterocyclic building block in your synthesis route and offer comprehensive technical support, including custom synthesis and bulk pricing. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.